Cytognomix has been invited to present applications of our ab initio sc probe targeted capture array technology and the Shannon software pipeline this fall at several venues in Italy.

18th Congress of the Italian Society of Human Genetics (SIGU) in Rome 25-28 September 2013 (platform) :   IDENTIFICATION, PREDICTION, AND PRIORITIZATION OF NON-CODING VARIANTS OF UNCERTAINSIGNIFICANCE IN HERITABLE BREAST CANCER.   P.K. Rogan1, E.J. Mucaki2, A. Stuart2, E. Dovigi1, C. Viner2, B. Shirley3, J.H. Knoll1, P. Ainsworth2.   1. Univ. Western Ontario, London, N6A 2C1 Canada and Molecular Bases of Genetic Risk and Genetic Testing, FondazioneIRCCS Inst. Nazionale dei Tumori,20133 Milano, Italy  2. Univ. Western Ontario    3. Cytognomix Inc., London ON Canada

Department of Biology, University of Padua, 3-October 2013 (host Stefania Bortoluzzi):  Deciphering variants of unknown significance that affect gene expression in inherited and somatic breast cancer

Institute of European Oncology, Milan, 30-October 2013 (hosts  Ugo Cavallaro and  Bernardo Bonanni),   “Clinical Science in Oncology Seminars” Program:  Deciphering variants of unknown significance that affect gene expression in inherited and somatic breast cancer

Invited presentation: “Deciphering variants of unknown significance in inherited breast cancer genes and exomes,” to the Clinical Cancer Genetics group of the Italian Society of Human Genetics (18th Incontro di Genetica Oncologica Clinica, SIGU), that will be held at the Policlinico S. Orsola in Bologna, Italy on July 19 2013 at 11 AM. We will describe predicted splicing, UTR and transcription factor binding site mutations, confirmed by RNASeq transcriptome data, and pathway analysis of the genes containing these mutations.